The latest report from a group financed and backed by the pharmaceutical industry “continues to misrepresent” the 340B Drug Pricing Program and its “successful 25-year history of helping hospitals stretch scarce financial resources to expand and improve access to lifesaving prescription drugs and comprehensive health services,” AHA Executive Vice President Tom Nickels writes today in an AHA Stat blog post. Nickels says the report “attempts to mislead the debate by comparing changes in the ‘charity care’ provided by a small sample size of 160 disproportionate share hospitals (out of 2,448 hospitals) that participate in the 340B program,” and he highlights the many benefits 340B hospitals provide to the patients and communities they serve. "We hope policymakers won’t be diverted by this self-serving report from the important job of finding solutions to bring down the exorbitant cost of many prescription drugs that is threatening the availability of life-saving medications for millions of Americans,” Nickels writes.

Headline
The Department of Health and Human Services and the Centers for Medicare & Medicaid Services released a proposed rule June 12 seeking to codify the…
Headline
The Centers for Medicare & Medicaid Services and the Department of Health and Human Services issued a request for information June 12 seeking input on CMS…
Headline
The AHA provided comments June 15 to the Centers for Medicare & Medicaid Services on its proposed rule establishing electronic standards for drug prior…
Headline
The Medicare Payment Advisory Commission June 15 released its June report to Congress that estimated the association between Medicare Advantage enrollment and…
Headline
The Medicaid and CHIP Payment and Access Commission June 15 released its June 2026 report to Congress. Among the topics discussed, chapter two focuses on…
Headline
The Centers for Medicare & Medicaid Services June 12 issued a final rule revising how the agency conducts oversight of accrediting organizations that…